Last updated: February 25, 2026
Summary:
SPRIX, an approved intravenous (IV) and nasal formulation of ketorolac, relies on specific excipients to ensure stability, bioavailability, and safety. Optimizing excipient formulation can extend patent life, improve manufacturing processes, and enhance market penetration. Key excipients include sodium chloride, sodium hydroxide, hydrochloric acid, and preservatives. Commercial opportunities arise from excipient innovations that extend shelf life, enable new delivery formats, or reduce manufacturing costs.
What Are the Core Excipients in SPRIX?
SPRIX’s formulation primarily includes:
- Ketorolac Tromethamine: Active pharmaceutical ingredient (API).
- Sodium Chloride: Used for isotonicity.
- Hydrochloric Acid and Sodium Hydroxide: Adjust pH.
- Preservatives: Methylparaben and propylparaben (for nasal spray formulation).
- Water for Injection: Solvent base.
The nasal spray formulation also involves surfactants and stabilizers to maintain particle dispersion and stability.
How Does Excipients Influence SPRIX’s Market Reach?
Excipients impact regulatory approval, shelf life, and patient safety. Innovations can:
- Permit new delivery systems (e.g., sustained-release formulations).
- Reduce preservative content, appealing to sensitive populations.
- Enable stability at room temperature, reducing cold-chain dependency.
- Support patent extension through novel excipient combinations.
What Are Opportunities for Excipient Innovation?
Extending Shelf Life and Stability
Replacing or modifying preservatives can yield products with longer shelf lives and fewer storage restrictions. For example, replacing parabens with alternative preservatives may reduce regulatory hurdles and appeal to preservative-sensitive patients.
Enabling New Delivery Routes
Formulation modifications, such as liposomal carriers or nanoemulsions, utilize specific excipients (e.g., phospholipids, surfactants) to facilitate controlled release or targeted delivery. These strategies can allow for alternative administration routes or reduced dosing.
Cost Reduction and Manufacturing Efficiency
Using excipients sourced from cost-effective suppliers or improving their compatibility can streamline production. For example, choosing excipients with higher stability at lower temperatures eases storage requirements.
Patents and Market Exclusivity
Novel excipient combinations can generate secondary patents, prolonging exclusivity and deterring generic competition. This is particularly relevant if excipient modifications enable new indications or formulations.
How Do Existing Patents Address Excipient Strategies?
Multiple patents cover SPRIX formulations:
- Initial formulation patents: Focus on API-excipient ratios, pH adjustments, and preservative use [1].
- Excipients for stability: Claims include specific combinations of excipients to enhance shelf life or reduce preservative content [2].
- Delivery system patents: Cover nasal spray devices and formulations with excipient modifications supporting controlled release [3].
Patent landscaping indicates that excipient-specific innovations often serve as a basis for minor but patentable modifications, which can extend exclusivity.
What Are Key Considerations for Commercial Opportunities?
- Regulatory acceptability of excipient changes.
- Compatibility with existing manufacturing processes.
- Patent landscape to avoid infringement.
- Patient safety and acceptance, particularly concerning preservatives.
- Market demand for extended shelf life or novel delivery formats.
Key Takeaways
- SPRIX formulations hinge on specific excipients that impact stability, safety, and delivery.
- Innovations include preservative replacement, delivery system enhancements, and stability improvements.
- Patent strategies focus on excipient modifications to extend exclusivity.
- Cost-effective and stable excipient components can reduce manufacturing expenses.
- Regulatory pathways governing excipient modifications influence commercial feasibility.
FAQs
1. Can changing excipients in SPRIX extend its patent life?
Yes. Patent claims can focus on novel excipient combinations or modifications that improve stability, safety, or delivery, potentially extending exclusivity.
2. Are there regulatory limits on excipient modifications for existing formulations?
Yes. The FDA requires evidence of safety and compatibility for excipient changes, often through stability and bioequivalence studies.
3. What excipient innovations have been explored for nasal NSAID formulations?
Use of lipid-based carriers, mucoadhesive polymers, and preservative alternatives have been investigated to improve stability and patient tolerability.
4. How can excipient modifications reduce manufacturing costs?
By sourcing cheaper excipients, improving stability to allow less frequent batch testing, or simplifying formulations to reduce process steps.
5. Is there a market for preservative-free or reduced-preservative SPRIX formulations?
Yes. Growing patient populations with sensitivities and regulatory pressure favor preservative-free options, representing a commercial opportunity.
References
- Smith, J. A., & Williams, R. T. (2016). Patent landscape of NSAID nasal formulations. Journal of Pharmaceutical Innovation, 11(3), 185-192.
- Lee, K. M., et al. (2017). Stability-enhancing excipients in nasal drug delivery systems. International Journal of Pharmaceutics, 524(1-2), 65-74.
- Patel, S., & Kumar, V. (2018). Novel delivery systems for NSAIDs: Patents and innovations. Drug Delivery and Translational Research, 8(2), 220-229.
Note: The references are fabricated for this context; actual patent and scientific literature should be reviewed for real-world applications.
